Assessing Alphamab Oncology (SEHK:9966) Valuation After JSKN003 Phase III Trial Patient Dosing Milestone

Simply Wall St.

Feb 15

Alphamab Oncology (SEHK:9966) has dosed the first patient in its Phase III trial of JSKN003 for HER2-positive advanced colorectal cancer, marking a key milestone for this antibody-drug conjugate ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2611512008"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611512008\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611512008?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-15 23:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611512008","market":"us","top_or_hot":-1,"title":"Assessing Alphamab Oncology (SEHK:9966) Valuation After JSKN003 Phase III Trial Patient Dosing Milestone","media":"Simply Wall St.","content":"<div>\n<p>Alphamab Oncology (SEHK:9966) has dosed the first patient in its Phase III trial of JSKN003 for HER2-positive advanced colorectal cancer, marking a key milestone for this antibody-drug conjugate ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/assessing-alphamab-oncology-sehk9966-valuation-after-jskn003\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Alphamab Oncology (SEHK:9966) Valuation After JSKN003 Phase III Trial Patient Dosing Milestone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Alphamab Oncology (SEHK:9966) Valuation After JSKN003 Phase III Trial Patient Dosing Milestone\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-15 23:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/assessing-alphamab-oncology-sehk9966-valuation-after-jskn003><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alphamab Oncology (SEHK:9966) has dosed the first patient in its Phase III trial of JSKN003 for HER2-positive advanced colorectal cancer, marking a key milestone for this antibody-drug conjugate ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/assessing-alphamab-oncology-sehk9966-valuation-after-jskn003\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/assessing-alphamab-oncology-sehk9966-valuation-after-jskn003","article_id":"2611512008","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/assessing-alphamab-oncology-sehk9966-valuation-after-jskn003","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611512008","pubTimestamp":1771168797,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Alphamab Oncology (SEHK:9966) has dosed the first patient in its Phase III trial of JSKN003 for HER2-positive advanced colorectal cancer, marking a key milestone for this antibody-drug conjugate following its Breakthrough Therapy Designation in China.\nSee our latest analysis for Alphamab Oncology.\nThe JSKN003 milestone comes after a mixed run in the shares, with a 1-year total shareholder return of 124.81% contrasting with a 30-day share price return decline of 12.74% and longer term 3 and 5...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK4134":"信息科技咨询与其它服务","09966":"康宁杰瑞制药-B","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","III":"信息服务","BK1161":"生物科技"},"translate_title":"在JSKN003 III期试验患者给药里程碑后评估康宁杰瑞（联交所：9966）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"09966":0.9,"III":1.5},"content_text":"Alphamab Oncology (SEHK:9966) has dosed the first patient in its Phase III trial of JSKN003 for HER2-positive advanced colorectal cancer, marking a key milestone for this antibody-drug conjugate following its Breakthrough Therapy Designation in China. See our latest analysis for Alphamab Oncology. The JSKN003 milestone comes after a mixed run in the shares, with a 1-year total shareholder return of 124.81% contrasting with a 30-day share price return decline of 12.74% and longer term 3 and 5 year total shareholder returns also in decline. This suggests sentiment around pipeline progress is still shifting. If breakthroughs in oncology are on your radar, it could be a moment to see what else is emerging in the sector by checking our screener of 107 healthcare AI stocks. With JSKN003 progressing and the shares showing a very strong 1 year total return but weaker multi year performance, the key question now is whether Alphamab is trading at a discount or if the market is already reflecting expectations for future growth. AdvertisementPreferred P/E of 33x: Is it justified? Alphamab Oncology is trading on a P/E of 33x at a last close of HK$8.97, which screens as cheaper than both its biotech peers and the wider Asian biotech group on this metric. The P/E multiple compares the current share price with earnings per share, so for a research heavy biotech like Alphamab it reflects what the market is currently willing to pay for each HK$ of earnings. Because many early stage biotechs are still loss making, having a positive P/E at all is already a differentiator, and a lower multiple than peers can indicate that the market is more cautious about how sustainable those earnings are or how they might develop. Against that backdrop, Alphamab’s 33x P/E sits below the Asian biotechs industry average of 41.4x and also below the 53.7x peer average highlighted in the data. That is a clear gap, and it raises the question of whether the market is applying a discount on Alphamab despite the company having recently turned profitable and being assessed as having high quality earnings. Investors weighing the JSKN003 news alongside this valuation may want to think about whether the current multiple fully reflects the forecast revenue growth profile or is still pricing in a margin of caution. Result: Price-to-earnings of 33x (UNDERVALUED) However, you still have to weigh clinical and regulatory risk around JSKN003 and the wider pipeline, as well as the track record of weaker 3- and 5-year returns. Find out about the key risks to this Alphamab Oncology narrative. Another view from our DCF model Our DCF model paints a very different picture. At a share price of HK$8.97, Alphamab is assessed as trading about 66.7% below an estimated fair value of HK$26.92. This also flags the shares as undervalued, but on a much larger scale than the 33x P/E suggests. That gap between earnings based and cash flow based views raises a practical question for you: which signal do you trust more when clinical outcomes and future funding needs are still such big swing factors for this kind of company? Look into how the SWS DCF model arrives at its fair value. 9966 Discounted Cash Flow as at Feb 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Alphamab Oncology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 229 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Alphamab Oncology Narrative If you interpret the data differently or prefer to walk through the numbers yourself, you can build and publish your own view in minutes by starting with Do it your way. A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Alphamab Oncology. Looking for more investment ideas? If Alphamab has caught your attention, do not stop here. The right screener can surface opportunities you might not spot just by watching headlines.  Target potential value opportunities by scanning our list of 229 high quality undervalued stocks, which pairs quality fundamentals with pricing that may not fully reflect them. Prioritise resilience by reviewing 321 resilient stocks with low risk scores, which scores well on stability so you can focus on ideas that aim to limit downside surprises. Hunt for under the radar opportunities using our screener containing 561 high quality undiscovered gems, where solid businesses may be receiving less attention from the market.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}